General MedicationsORALGeneric
STRATTERA
ATOMOXETINE HYDROCHLORIDE
Standard Dose
EQ 5MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: 901 REQUIRED Marketing status: Discontinued
Summary
Approval overview STRATTERA is listed in Drugs@FDA under application 021411 (NDA).
Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient ATOMOXETINE HYDROCHLORIDE Form and strength CAPSULE;ORAL - EQ 5MG BASE Sponsor LILLY Submission history Latest submission status date: 2022-01-06 00:00:00.
Structured Monograph
Clinical summary
Approval overview STRATTERA is listed in Drugs@FDA under application 021411 (NDA). Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient ATOMOXETINE HYDROCHLORIDE Form and strength CAPSULE;ORAL - EQ 5MG BASE Sponsor LILLY Submission history Latest submission status date: 2022-01-06 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: 901 REQUIRED
Interaction Notes
- No interaction notes stored yet.